Checkpoint inhibitors (PD-1 / PD-L1 / CTLA-4)
Oncology· 16 reviewed drugs· 61351 cited findings behind them
What the regulatory reviews cover
This library includes several checkpoint inhibitors (PD-1 / PD-L1 / CTLA-4) that have undergone regulatory review. Keytruda was reviewed for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, showing an Objective Response Rate (pembrolizumab arm) of 74.4% compared to a placebo arm of 51.9%. Opdivo was reviewed for first-line metastatic NSCLC, among other indications, with a Median Overall Survival of 15.7 months. Yervoy was reviewed for unresectable or metastatic melanoma, demonstrating an OS improvement of 3 months. Bavencio was reviewed for Merkel cell carcinoma and maintenance treatment of urothelial carcinoma, with a Median overall survival (avelumab) of 21.4 months compared to a comparator arm of 14.3 months.
Other drugs in this class include Tevimbra, JEMPERLI, Zynyz, Tecentriq, Opdualag, Imjudo, Loqtorzi, KEYTRUDA QLEX, and Libtayo, each reviewed for various indications such as NSCLC, endometrial cancer, Merkel cell carcinoma, and squamous cell carcinoma. For instance, Zynyz showed an Objective response rate (ORR) of 52.3% for Merkel cell carcinoma. It is important to note that these drugs were studied in different trials, and therefore, the reported figures are not directly comparable in a head-to-head manner.
The drugs — one cited result each
| Keytruda Merck & Co., Inc. | Objective Response Rate (pembrolizumab arm): 74.4 Keytruda FDA Review, p.132 |
| Opdivo Bristol-Myers Squibb Company | Median Overall Survival: 15.7 months Bristol-Myers Squibb Company — Opdivo FDA Review (NDA/BLA 12, p.65 |
| Yervoy Bristol-Myers Squibb Company | OS improvement: 3 months Bristol-Myers Squibb Company — Yervoy EMA EPAR variation ass, p.147 |
| Tevimbra BeOne Medicines Ltd. | PFS2 stratified Hazard Ratio (95% CI): 0.71 (0.57, 0.89) BeOne Medicines Ltd. — Tevimbra EMA EPAR variation assessmen, p.57 |
| JEMPERLI GSK plc | ORR: 9 GSK plc — Jemperli EMA EPAR variation assessment report (EME, p.38 |
| Zynyz Incyte Corporation | Objective response rate (ORR): 52.3 Incyte Corporation — Zynyz EMA EPAR public assessment report, p.113 |
| Tecentriq Roche Holding AG | Median overall survival (months): 12.6 GENENTECH INC — Tecentriq FDA Summary Review (NDA/BLA 761041, p.4 |
| Bavencio Merck B V | Median overall survival (avelumab): 21.4 EMD SERONO INC — Bavencio FDA Review (NDA/BLA 761049, 2020), p.107 |
| Opdualag Bristol-Myers Squibb Company | Median PFS (months): 10.15 Bristol-Myers Squibb Company — Opdualag EMA EPAR public asse, p.82 |
| Imjudo AstraZeneca PLC | Median OS for sorafenib vs placebo in advanced HCC: 10.7 vs 7.9 AstraZeneca PLC — Imjudo EMA EPAR public assessment report (, p.12 |
| Loqtorzi Topalliance Biosciences | BIRC-determined PFS: 21.4 months Topalliance Biosciences — Loqtorzi EMA EPAR public assessmen, p.138 |
| OPDIVO QVANTIG Bristol-Myers Squibb Company | 618 cited findings on the drug page → |
| KEYTRUDA QLEX Merck & Co., Inc. | 558 cited findings on the drug page → |
| Kimmtrak / tebentafusp Immunocore | 355 cited findings on the drug page → |
| Imfinzi AstraZeneca PLC | 294 cited findings on the drug page → |
| Libtayo Regeneron Pharmaceuticals, Inc. | Confirmed Objective Response Rate (ORR) for metastatic CSCC (LIBTAYO 3 mg/kg every 2 weeks): 49 Regeneron Pharmaceuticals, Inc. — Libtayo FDA Review (NDA/BL, p.24 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.